Identification | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Aztreonam | ||||||||||||
Accession Number | DB00355 (APRD00815, EXPT00605) | ||||||||||||
Type | small molecule | ||||||||||||
Description | A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. [PubChem] | ||||||||||||
Structure |
|
||||||||||||
Categories (*) | |||||||||||||
Molecular Weight | 435.433 | ||||||||||||
Groups | approved | ||||||||||||
Monoisotopic Weight | 435.051853925 | ||||||||||||
Pharmacology | |||||||||||||
Indication | For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections. | ||||||||||||
Mechanism of action | The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that aztreonam interferes with an autolysin inhibitor. | ||||||||||||
Absorption | Less than 1% absorbed from the gastrointestinal tract following oral administration. Completely absorbed following intramuscular administration. | ||||||||||||
Protein binding | Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%. | ||||||||||||
Biotransformation | Approximately 6 to 16% metabolized to inactive metabolites by hydrolysis of the beta-lactam bond, resulting in an open-ring compound. | ||||||||||||
Route of elimination | In healthy subjects, aztreonam is excreted in the urine about equally by active tubular secretion and glomerular filtration. Urinary excretion of a single parenteral dose was essentially complete by 12 hours after injection. | ||||||||||||
Toxicity | Not Available | ||||||||||||
Affected organisms |
|
||||||||||||
Interactions | |||||||||||||
Drug Interactions |
|
||||||||||||
Food Interactions | Not Available |
Penicillin-binding protein 3 | |
---|---|
Name | Penicillin-binding protein 3 |
Gene Name | pbpC |
Pharmacological action | yes |
Actions | inhibitor |
References |
|
DTHybrid score | 0.9145 |
Beta-lactamase | |
Name | Beta-lactamase |
Gene Name | ampC |
Pharmacological action | yes |
Actions | potentiator |
References |
|
DTHybrid score | 0.0611 |